---
document_datetime: 2025-06-16 15:16:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/xbryk-epar-all-authorised-presentations_en.pdf
document_name: xbryk-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6909493
conversion_datetime: 2025-12-18 23:30:39.474139
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Content (concentration) Pack size

| EU/1/24/1889/001   | Xbryk   | 120 mg   | Solution for injection   | Subcutaneous use   | vial (glass)   | 1.7 ml (70 mg/ml)   | 1 vial   |
|--------------------|---------|----------|--------------------------|--------------------|----------------|---------------------|----------|
| EU/1/24/1889/002   | Xbryk   | 120 mg   | Solution for injection   | Subcutaneous use   | vial (glass)   | 1.7 ml (70 mg/ml)   | 3 vials  |